MARS Bioimaging Ltd has secured $15.0 million in investment capital from investors. The funding round provides significant backing for the company, which was established in 2007 to commercialise its innovative MARS imaging system for applications in medical diagnosis.
The MARS imaging system represents a significant advancement in medical technology. It is built upon the new generation Medipix chip, licensed from CERN in Switzerland, and incorporates technology developed by the University of Canterbury (UC) and its partners. This system has emerged as the world’s leading spectral, or multi-energy ‘true colour’, imaging technology. Notably, it is the first commercially available spectral, high definition computed tomography (CT) system, having already demonstrated promising applications in various fields.
This capital infusion marks a pivotal moment for MARS Bioimaging Ltd, enabling the company to accelerate its strategic objectives and solidify its position in the advanced medical imaging market. The funds are earmarked to further advance the development and refinement of the MARS imaging system, enhance its commercialisation efforts globally, and expand its market presence. This investment will also support scaling the company's operational capabilities, including research and development initiatives, to meet growing demand and explore new opportunities within the medical imaging sector.
With this substantial investment, MARS Bioimaging Ltd is strategically positioned to build upon its technological leadership and expand the reach of its groundbreaking system. The company aims to continue its trajectory of innovation, bringing its advanced imaging solutions to a broader range of medical professionals and patients, thereby contributing to improved diagnostic capabilities and outcomes globally.
%20(NZAX%3A%20CRP)%20(FSE%3A%20%203GRE).png&w=3840&q=75)
.png&w=3840&q=75)
